Search results for "Low-Density Lipoprotein"

showing 10 items of 172 documents

Changes in Serum and Lipoprotein Fatty Acids of Growing Rats Fed Protein-Deficient Diets with Low or Adequate Linolenic Acid Concentrations

1992

The effects of a protein-deficient diet associated with sunflower oil [adequate in 18:2(n-6), poor in 18:3(n-3)] or soybean oil [adequate in both 18:2(n-6) and 18:3(n-3)] on lipid serum and lipoprotein compositions were studied in growing rats. Four groups of rats were fed different diets: SFC (20% casein + 5% sunflower oil); SFd (2% casein + 5% sunflower oil); SC (20% casein + 5% soybean oil); Sd (2% casein + 5% soybean oil). After 28 d, both protein-deficient groups exhibited low concentrations of protein, phospholipid, triacylglycerol and total cholesterol in serum and VLDL. Compared with rats fed 20% casein diets, those fed low protein diets had lower 18:2(n-6) and 20:4(n-6) in phosphol…

MaleVery low-density lipoproteinmedicine.medical_specialtyfood.ingredientLow proteinLinolenic AcidsLinolenic acidLipoproteinsMedicine (miscellaneous)Lipoproteins VLDLBiologySoybean oilfoodProtein DeficiencyInternal medicineCaseinmedicineAnimalsFood sciencePhospholipidsTriglycerideschemistry.chemical_classificationNutrition and DieteticsSunflower oilFatty AcidsFatty acidRats Inbred StrainsRatsEndocrinologychemistryHelianthuslipids (amino acids peptides and proteins)SoybeansLipoproteins HDLPolyunsaturated fatty acidThe Journal of Nutrition
researchProduct

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

2008

Background Patients with chronic kidney disease (CKD) have an increased risk for cardiovascular events (CVE). Uraemic dyslipidaemia, which is characterized by low HDL-cholesterol (HDL-C) and elevated triglycerides' levels, may contribute to this elevated cardiovascular risk. Cholesteryl ester transfer protein (CETP) lowers HDL-C by transferring cholesterol esters to LDL and VLDL particles. We tested the hypothesis that CETP activity is associated with CVE in patients with CKD stage V. Methods We measured CETP activity and cholesterol levels in 69 haemodialysis patients. CVE and death were prospectively assessed over a follow-up period of 48 months. Results CETP activity was negatively corre…

MaleVery low-density lipoproteinmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionKaplan-Meier EstimateSeverity of Illness IndexCohort Studieschemistry.chemical_compoundPredictive Value of TestsRisk FactorsInternal medicineCholesterylester transfer proteinmedicineHumansMyocardial infarctionProspective StudiesAngioplasty Balloon CoronaryCoronary Artery BypassProspective cohort studyStrokeAgedAged 80 and overTransplantationbiologybusiness.industryCholesterolCholesterol HDLMiddle Agedmedicine.diseaseCholesterol Ester Transfer Proteinscarbohydrates (lipids)StrokeEndocrinologychemistryNephrologyChronic Diseasebiology.proteinlipids (amino acids peptides and proteins)FemaleKidney DiseasesStentsHemodialysisbusinessBiomarkersKidney diseaseFollow-Up StudiesNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes

2010

Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbA1c] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased …

Malehigh-density lipoproteinsmedicine.medical_specialtyType 2 diabetes030204 cardiovascular system & hematologysizeStatistics NonparametricRosiglitazone03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicinelow-density lipoproteinsHumansHypoglycemic AgentsProspective Studies030212 general & internal medicineGlycated Hemoglobindiabetesbusiness.industryFastingMiddle AgedPostprandial Periodmedicine.diseaseLipids3. Good healthLipoproteins LDLPostprandialEndocrinologyDiabetes Mellitus Type 2FemaleThiazolidinedioneslipids (amino acids peptides and proteins)HemoglobinsubclassesLipoproteins HDLCardiology and Cardiovascular MedicineRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugLipoprotein
researchProduct

Statin Treatment and Prognosis of Elderly Patients Discharged after Non-ST Segment Elevation Acute Coronary Syndrome

2019

<b><i>Background:</i></b> Statins are recommended for secondary prevention. Our aims were to describe the proportion of very elderly patients receiving statins after non-ST segment elevation acute coronary syndrome (NST-ACS) and to determine the prognostic implications of statins use. <b><i>Methods:</i></b> This prospective registry was performed in 44 hospitals that included patients ≥80 years discharged after a NST-ACS from April 2016 to September 2016. <b><i>Results:</i></b> We included 523 patients, the mean age was 84.2 ± 4.0 years and 200 patients (38.2%) were women. Previous statin treatment was recorded in 282 p…

Malemedicine.medical_specialtyAcute coronary syndromeFrail ElderlyAncianoEnfermedad cardiovascularComorbidity030204 cardiovascular system & hematologyTratamiento médico03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEnfermos cardíacosmedicineHumansST segmentPharmacology (medical)Prospective StudiesRegistriesAcute Coronary SyndromeNon-ST Elevated Myocardial InfarctionAged 80 and overLdl cholesterolSecondary preventionbusiness.industryMean ageCholesterol LDLStatin treatmentPrognosismedicine.diseaseComorbidityPatient DischargechemistrySpain030220 oncology & carcinogenesisLow-density lipoproteinFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAncianosFollow-Up StudiesCardiology
researchProduct

Effect of Dietaryn-3Polyunsaturated Fatty Acids on Oxidant/Antioxidant Status in Macrosomic Offspring of Diabetic Rats

2014

The aim of this work was to determine the effect of dietaryn-3PUFA on oxidant/antioxidant status,in vitrovery low and low density lipoprotein (VLDL-LDL), and VLDL-LDL-fatty acid composition in macrosomic pups of diabetic mothers. We hypothesized thatn-3PUFA would improve oxidative stress in macrosomia. Diabetes was induced in female Wistar rats fed with the ISIO diet (control) or with the EPAX diet (enriched inn-3PUFAs), by streptozotocin. The macrosomic pups were killed at birth (day 0) and at adulthood (day 90). Lipid parameters and VLDL-LDL-fatty acid composition were investigated. The oxidant/antioxidant status was determined by measuring plasma oxygen radical absorbance capacity (ORAC)…

Malemedicine.medical_specialtyAntioxidantArticle SubjectOxygen radical absorbance capacitymedicine.medical_treatmentlcsh:Medicinemedicine.disease_causedigestive systemAntioxidantsGeneral Biochemistry Genetics and Molecular BiologyDiabetes Mellitus ExperimentalFetal Macrosomiachemistry.chemical_compoundInternal medicineDiabetes mellitusFatty Acids Omega-3medicineAnimalsRats Wistarchemistry.chemical_classificationGeneral Immunology and Microbiologylcsh:Rnutritional and metabolic diseasesLipid metabolismGeneral MedicineOxidantsStreptozotocinmedicine.diseaseDietary FatsRatsOxidative StressEndocrinologychemistryLow-density lipoproteinFemalelipids (amino acids peptides and proteins)Oxidation-ReductionOxidative stressResearch Articlemedicine.drugPolyunsaturated fatty acidBioMed Research International
researchProduct

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the Euro…

2014

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive pati…

Malemedicine.medical_specialtyChinaPhysiologyBlood Pressurelaw.inventionchemistry.chemical_compoundCognitionRandomized controlled triallawRecurrenceInternal medicineInternal MedicinemedicineSecondary Preventionblood pressure; cognitive decline; low-density lipoprotein cholesterol; randomized controlled trial; secondary prevention; strokeDementiaHumansProspective StudiesCognitive declineProspective cohort studyStrokeAntihypertensive AgentsAgedLdl cholesterolCholesterolbusiness.industryBlood Pressure DeterminationCholesterol LDLlipoprotein cholesterol randomized controlled trial secondary prevention strokeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseblood pressure cognitive decline low-densityEuropeStrokeBlood pressurechemistryIschemic Attack TransientHypertensionPhysical therapyCardiologyDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessCognition Disorders
researchProduct

Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a multicenter Italian study.

2009

Abstract Background and aims Plant sterols, added to several food sources, lower serum cholesterol concentrations. Plant sterol-induced cholesterol lowering is paralleled by a mild decrease in plasma levels of the antioxidant β-carotene, the amount of this decrease being considered clinically non-significant. Whether the effect on lipid profile of daily consumption of plant sterol-enriched low-fat fermented milk (FM) is paralleled by a concomitant variation in a reliable marker of the oxidative burden like plasma isoprostane levels is unresolved. Methods and results The effect of plant sterol consumption on plasma lipid and isoprostane levels of hypercholesterolemic patients was evaluated i…

Malemedicine.medical_specialtyIsoprostaneAntioxidantTime FactorsCultured Milk ProductsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentCampesterolHypercholesterolemiaMedicine (miscellaneous)IsoprostanesDinoprostAntioxidantschemistry.chemical_compoundDouble-Blind MethodInternal medicinePhytosterolmedicineHumansNutrition and Dieteticsmedicine.diagnostic_testHypercholesterolemia; Isoprostanes; Phytosterols;Cholesterolbusiness.industryPhytosterolAnticholesteremic AgentsPhytosterolsMiddle AgedOxidative StressSterolsEndocrinologyCholesterolTreatment OutcomechemistryItalyLow-density lipoproteinFood Fortified8 isoprostanelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineLipid profilebusiness
researchProduct

Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.

2014

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these…

Malemedicine.medical_specialtyPhysiologyHypercholesterolemiaLow density lipoprotein cholesterolBlood Pressurelaw.inventionCognitionRandomized controlled triallawRecurrenceInternal medicineblood pressure cognitive decline low-density lipoprotein cholesterol primary prevention secondary prevention strokeInternal MedicineSecondary PreventionMedicineHumansCognitive declineStrokeBeneficial effectsRandomized Controlled Trials as TopicSecondary preventionbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECholesterol LDLmedicine.diseasePrimary PreventionStrokeBlood pressureCholesterolCardiologyPhysical therapylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessStroke incidenceCognition Disordersblood pressure; cognitive decline; low-density lipoprotein cholesterol; primary prevention; secondary prevention; strokeJournal of hypertension
researchProduct

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaIntention to Treat AnalysiHypercholesterolemiaUrologyalirocumabBococizumabPharmacologyPlaceboAged; Antibodies Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Drug Therapy Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Male; Middle Aged; Medicine (all)law.inventionchemistry.chemical_compoundcardiovascular eventsDouble-Blind MethodRandomized controlled triallawCardiovascular DiseaseAnticholesteremic AgentMedicineproprotein convertase subtilisin–kexin type 9 (PCSK9)High Cardiovascular Risk PatientsAgedAlirocumabalirocumab; cholesterol; cardiovascular eventsCholesterolbusiness.industryMedicine (all)PCSK9Antibodies MonoclonalcholesterolCholesterol LDLGeneral MedicineMiddle AgedLomitapideEvolocumabchemistrylow-density lipoprotein (LDL) cholesterol[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHumanNew England journal of medicine
researchProduct

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

2014

The first observations linking a low serum level of HDL-C to increased risk for cardiovascular disease were made over 50 years ago. High serum levels of HDL-C appear to protect against the development of atherosclerotic disease, while low serum levels of this lipoprotein are among the most important predictors of atherosclerotic disease in both men and women and people of all racial and ethnic groups throughout the world. It has long been assumed that therapeutic interventions targeted at raising HDL-C levels would lower risk for such cardiovascular events as myocardial infarction, ischemic stroke, and death. Even after five decades of intensive investigation, evidence to support this assum…

Malemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismDiseaseLower riskNiacinlaw.inventionCoronary artery diseaseEndocrinologyRandomized controlled triallawRisk FactorsInternal medicinemedicineHumansMyocardial infarctionDyslipidemiasbusiness.industryReverse cholesterol transportCholesterol HDLFibric Acidsmedicine.diseaseEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleThiazolidinedionesHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinesscoronary artery disease fibrate high-density lipoproteins low-density lipoproteins niacin reverse cholesterol transport statin thiazolidinedioneNiacin
researchProduct